Learn More
Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is(More)
AIM Trastuzumab (T), a humanised monoclonal antibody against HER-2, is active in HER-2-positive MBC patients. However, nearly 60% of the patients do not benefit from T, stressing the need for(More)
838 Background: Age ≥60 years is considered among the possible risk factors of H related cardiac toxicity. METHODS Between 1/99 and 5/02 two compassionate use programs were run in Belgium to(More)
  • 1